Showing 21-30 of 30 results for "".
Physician Spotlight: Vivian Y. Shi, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-vivian-y-shi-md/23749/Procedural Management for HS
https://practicaldermatology.com/programs/practical-dermatology/procedural-management-for-hs/35891/Vivian Shi, MD, talks about procedural management for hidradenitis suppurativa and how to incorporate those procedures with medical management of the condition at Music City SCALE 2025.Acne and Rosacea: Quality of Life and Lifestyle Insights
https://practicaldermatology.com/topics/acne-rosacea/acne-and-rosacea-quality-of-life-and-lifestyle-insights/23516/Acne and rosacea have causes and effects well beyond the skin.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-10/23206/Hidradenitis Suppurativa Treatment and the Use of Ultrasound
https://practicaldermatology.com/topics/rare-disease/hidradenitis-suppurativa-treatment-and-the-use-of-ultrasound/24013/Experts highlight recent research and treatment advancements in hidradenitis suppurativa.Medical Education and Technology: Intertwined like the Rod of Asclepius
https://practicaldermatology.com/columns/clinical-focus-1/medical-education-and-technology-intertwined-like-the-rod-of-asclepius/23453/Current Sunscreen Controversies Impeding Patient Compliance
https://practicaldermatology.com/topics/practice-management/current-sunscreen-controversies-impeding-patient-compliance/20992/Patient concerns should not prevent the physician from advising adequate sunscreen use.Building the Skin Care Regimen: Choosing the Right Ingredients
https://practicaldermatology.com/topics/general-topics/building-the-skin-care-regimen-choosing-the-right-ingredients/21846/Four primary product types provide the basis for a skincare regimen that ensures the health and optimized function of the skin.- Bimekizumab Trials 'Raise the Bar' for HS, Dr. Vivian Shi Sayshttps://practicaldermatology.com/news/Bimekizumab-Trials-Raise-Bar-HS-Dr-Vivian-Shi-Says/2473933/More than half of hidradenitis suppurativa (HS) patients treated with bimekizumab (BIMZELX, UCB) had no draining tunnels (DTs) at 2 years, and 63.6% reported no or mild skin pain, compared to 10.0% at baseline, according to new data presented at the 2025 American Academy of Dermatology (AAD) Annu
- Vivian Shi, MDhttps://practicaldermatology.com/profiles/vivian-shi-md/jRx32b/
- Previous
- Next